OBJECTIVES The study sought to explore sex-related differences in coronary atheroma regression following high-intensity statin therapy.
O ver the course of the last 2 decades, randomized clinical trials and meta-analyses demonstrated the unequivocal benefits of statin-mediated cholesterol lowering in the prevention of cardiovascular events (1) (2) (3) . Recent guidelines have shifted emphasis away from targeting specific low-density lipoprotein cholesterol (LDL-C) goals, and now endorse the broad use of high-intensity statins in all individuals with atherosclerotic cardiovascular disease (4) . Despite the enrollment of both sexes in clinical trials employing statins, the antiatherosclerotic effects of high-intensity statins in women compared with men remains relatively unexplored. Moreover, some continue to question the merits of statins in women (5, 6) , particularly in the primary preventative setting. Much of this controversy stems from the consistent under-representation of women in randomized clinical trials (7) . Although cardiovascular events are a leading cause of death in women, debate regarding the benefits of statins, in addition to other therapeutic strategies, may contribute to a sex disparity in the implementation of evidence-based strategies for the treatment of cardiovascular disease (8, 9) . Intravascular ultrasound (IVUS) enabled characterization of factors promoting coronary atheroma progression and for quantifying the ability of antiatherosclerotic strategies to slow disease progression. Although high doses of potent statins can regress coronary atheroma (10, 11) , and lower clinical event rates (12, 13) , there are currently no reports of differential sex-related effects of highintensity statin therapy. The SATURN (Study of Coronary Atheroma by Intravascular Ultrasound:
Effect of Rosuvastatin Versus Atorvastatin) study was a randomized controlled trial employing serial IVUS to evaluate the antiatherosclerotic efficacy of rosuvastatin and atorvastatin, each prescribed at their highest approved doses during a 24-month study period (11) . By performing a posthoc subgroup analysis of the SATURN study, we tested the hypothesis that there would be sexspecific variations in the effects of maximally intensive statin therapy on coronary atheroma progression.
METHODS
PATIENT SELECTION. The design of the SATURN study has been previously described (14) . Briefly, patients with angiographically demonstrable coronary disease and LDL-C <116 mg/dl following a 2-
week treatment period with atorvastatin 40 mg or rosuvastatin 20 mg daily, were re-randomized and and patients whose baseline imaging met these requirements were eligible for randomization.
Following 104 weeks of treatment, patients underwent a second IVUS of the same artery. Anatomically-matched arterial segments were selected for analysis on the basis of proximal and distal landmarks. Cross-sectional images spaced 1 mm apart were selected for analysis, with lumen and external elastic membrane (EEM) leading edges defined by manual planimetry. Plaque area was determined as the area between these leading edges. Percent atheroma volume (PAV) (a measure of plaque burden representing the percent of the EEM volume occupied by atheroma), the primary efficacy endpoint in the SATURN study, was calculated as previously described (15) . Total atheroma volume (TAV) (simply the gross volume of atheroma normalized for length), the secondary efficacy endpoint in the SATURN study, was also calculated as previously described (15) . Change in plaque burden was calculated as the PAV (or TAV) at 104 weeks minus the corresponding PAV (or TAV) at baseline. Plaque regression was defined as any decrease in PAV (or TAV) from baseline. The post-hoc analyses presented here pooled results from both treatment groups, as in the SATURN study, rosuvastatin and atorvastatin did not differ in the primary efficacy endpoint of the change in PAV from baseline. results regarding the efficacy of statins in women (21, 22) . This inconsistency has created confusion and controversy among physicians, resulting in some openly questioning the merits of prescribing statins to women (5,23,24), despite clinical trials that enrolled both men and women reporting benefit (25) . Baseline values are reported as mean AE SD, and change values are reported as least-squares mean AE SE after controlling for the respective baseline value. All p values reflect comparisons between women and men.
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RESULTS P A T I E N T C H A R A C T E R I S T I C S .
EEM ¼ external elastic membrane; IVUS ¼ intravascular ultrasound. Values are least-squares mean AE SE. Coronary syndrome was designated as the mode of presentation for the initial coronary angiogram during the time in which baseline intravascular ultrasound (IVUS) and study enrollment occurred.
PAV ¼ percent atheroma volume; other abbreviations as in Table 2 . Puri et al. Australia. E-mail: stephen.nicholls@sahmri.com.
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